Clinical trials: Cold
Common Cold, Immunity
Effects of LP28 on Immunity Enhancement in the Elderly
Due to the increasing attention on aging-related health issues, this study focuses on the elderly population as participants. The aim is to investigate whether supplementation with Lactobacillus plantarum LP28 can effectively…
- Conditions
- Common Cold, Immunity, Probiotic
- Trial name
- NCT06724185
- Testing
- LP28 capsule
- Where
- 2 sites in Taiwan
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Synbio Tech Inc.
Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
Cold Agglutinin Disease Real World Evidence Registry
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS).
- Trial name
- CADENCE (NCT05791708)
- Testing
- Sutimlimab
- Where
- 68 sites in United States, Austria and 6 more
- Volunteers
- 429 people
- Sponsor
- RECORDATI GROUP
Upper Respiratory Disease, Influenza
Immune Defense Protein Impact On Respiratory Immune Outcomes
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season.
- Conditions
- Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
- Trial name
- NCT07431840
- Testing
- Immune Defense Protein 50mg Dose, IDP 200mg Dose
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Quantec Ltd
Chronic Obstructive Lung Disease (COLD)
Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD
This clinical trial evaluates the long-term safety and efficacy of 0.75 mg HSK39004 Dry Powder Inhaler administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive…
- Trial name
- NCT07425210
- Testing
- HSK39004 Dry Powder Inhaler -0.75mg BID
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Common Cold, Cough
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on…
- Trial name
- NCT06716645
- Testing
- Robitussin Maximum Strength Cough and Chest Congestion DM, Robitussin Maximum Strength Nighttime Cough DM
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- HALEON
Chronic Rhinitis
A Study of RhinAer Stylus for Treating Chronic Rhinitis
Post-market study to continue to evaluate the effectiveness of the RhinAer Stylus for chronic rhinitis and the effect of treatment on inflammatory biomarkers.
- Trial name
- BIOKLEAR (NCT06599736)
- Testing
- RhinAer Stylus
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Aerin Medical
Hypothermia Due to Cold Environment
Clinical Evaluation of Effectiveness of the "Therm'Up" Heating Device
Here's a concise summary in English without the numbers: Hypothermia is defined as a core temperature below 35°C and occurs when the body loses more heat than it produces.
- Trial name
- NCT06788925
- Testing
- Patients support with survival coverage, Patients support with active thermic jacket
- Where
- France
- Volunteers
- 100 people
- Sponsor
- ThermoTrauma
Cellular Injury and Post-Cryogenic Recovery, Cryogenic Cellular Stress
Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)
This laboratory-based study evaluates the effects of controlled cryogenic preservation on human cell samples using Truway Health's in-vitro cryo therapeutic methodology.
- Conditions
- Cellular Injury and Post-Cryogenic Recovery, Cryogenic Cellular Stress, Cold-Induced Cellular Injury, Thermal Injury Response
- Trial name
- CRYO-IVT (NCT07321028)
- Testing
- Standard Laboratory Cryopreservation Procedure, Enhanced Laboratory Cryopreservation Procedure, Normothermic Cell Culture Control
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Truway Health, Inc.
Flu, Cold
Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula
The goal of this interventional clinical trial is to test the effectiveness of enhancing immunity in newly born infants fed with Feihe investigational formula product containing Lactoferrin fortified with HMO.
- Trial name
- NCT06158659
- Testing
- Feihe Investigational Formula, Control Formula, Breastfeeding
- Where
- 3 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Heilongjiang Feihe Dairy Co. Ltd.
Sore-throat, Common Cold
A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Throat Spray on the Incidence and Duration of Sickness
This is a randomized, triple-blind, placebo-controlled clinical trial evaluating the effects of Beekeeper's Naturals Propolis Immune Support Throat Spray on the incidence and duration of sickness over a 16-week period.
- Trial name
- NCT07246850
- Testing
- Beekeeper's Propolis Throat Spray
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Beekeeper's Naturals Inc
Cold Agglutinin Disease
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin…
- Trial name
- NCT05096403
- Testing
- Pegcetacoplan
- Where
- 44 sites in United States, Austria and 12 more
- Volunteers
- 24 people
- Sponsor
- Swedish Orphan Biovitrum
Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
The main purpose of this study was to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.
- Trial name
- NCT05086744
- Testing
- Iptacopan
- Where
- 8 sites in United States, Germany and 4 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself.
- Conditions
- COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection, Rhinovirus, Virus Diseases
- Trial name
- NCT06149494
- Testing
- Vapendavir
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Altesa Biosciences, Inc.
AIHA - Cold Autoimmune Hemolytic Anemia
Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
This is a multicenter, open-label, single-arm Phase I clinical trial to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection treatment in autoimmune hemolytic anemia that has failed at least three lines of…
- Trial name
- NCT07091370
- Testing
- Inaticabtagene Autoleucel Injection
- Volunteers
- 12 people
- Sponsor
- Juventas Cell Therapy Ltd.
Cold Agglutinin Disease
Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan
This was a multi-center, single treatment-group, open-label study to provide sutimlimab to the adult participants with cold agglutinin disease (CAD) who had completed the CARDINAL (NCT number: NCT03347396) or CADENZA (NCT number…
- Trial name
- NCT05132127
- Testing
- sutimlimab
- Where
- 5 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Sanofi
Cold Urticaria
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
Primary Objective: To demonstrate the efficacy of dupilumab in adult and adolescent participants with primary acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of an H1-antihistamine…
- Trial name
- NCT04681729
- Testing
- Dupilumab SAR231893, Non sedating H1-antihistamine
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
Acute Respiratory Tract Infection, Flu, Human
Effectiveness of a Nasal Spray on Viral Respiratory Infections
There is no cure for cold or flu, most people recover in about within two weeks. Paracetamol may be used to reduce aches or treat fever, headache, or body aches.
- Conditions
- Acute Respiratory Tract Infection, Flu, Human, COVID-19, Common Cold
- Trial name
- NCT06278324
- Testing
- Nasal Spray HSV Treatment
- Where
- France
- Volunteers
- 76 people
- Sponsor
- CEN Biotech
Cold Sores
Post-marketing Study for the Evaluation of Profilm Cold Sores
Experimental clinical study with a post-marketing, prospective, intra-subject controlled design to evaluate the efficacy and safety of the use of a medical device for the treatment of cold sores, over a maximum period of two…
- Trial name
- NCT06734728
- Testing
- Profilm Cold Sores
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- i+Med S.Coop.
Common Cold, Sore-throat
Efficacy and Safety of Silfamin for Common Cold
This is a 2-arm, prospective, randomized, double-blind, placebo-controlled, and three-days-treatment clinical study comparing the efficacy and safety of Silfamin at a dose of 2 tablets@150 mg twice daily in subjects with common…
- Trial name
- NCT06497439
- Testing
- Silfamin
- Where
- 2 sites in Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
Common Cold, Allergy
Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)
Healsea® Children is a seawater-based nasal spray supplemented with a natural Symbiofilm® extract (0.02%) isolated from marine bacteria.
- Trial name
- NCT05034328
- Testing
- Healsea® Children, Conventional therapies for common cold
- Where
- 15 sites in Poland
- Volunteers
- 186 people
- Sponsor
- Lallemand Pharma AG